Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LB 100

Drug Profile

LB 100

Alternative Names: LB-1; LB-100

Latest Information Update: 17 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer City of Hope National Medical Center; Grupo Espanol de Investigacion en Sarcomas; INSERM; Lixte Biotechnology Holdings; National Cancer Institute (USA)
  • Class Anti-ischaemics; Antidepressants; Antineoplastics; Behavioural disorder therapies; Carboxylic acids; Heterocyclic bicyclo compounds; Piperazines; Small molecules
  • Mechanism of Action Protein phosphatase 2A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Myelodysplastic syndromes; Soft tissue sarcoma
  • Phase I Small cell lung cancer
  • Preclinical Angelman syndrome; Behavioural disorders
  • No development reported Ischaemia; Solid tumours
  • Discontinued Depressive disorders; Haematological disorders

Most Recent Events

  • 13 Oct 2022 Lixte Biotechnology Holdings announces intention to submit applications for trial approvals in other EU countries
  • 13 Oct 2022 Spanish Agency for Medicines and Health Products approves phase I/II trial for Soft tissue sarcoma (First-line therapy, Late-stage disease, Combination therapy)
  • 13 Oct 2022 Lixte Biotechnology in collaboration with Grupo Espanol de Investigacion en Sarcomas plans a phase I/II trial for Soft tissue sarcoma (First-line therapy, Late-stage disease, Combination therapy) in first quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top